Network mapping of molecular biomarkers influencing radiation response in rectal cancer
File(s)Network-Mapping-of-Molecular-Biomarkers.pdf (1.32 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Introduction
Pre-operative radiotherapy (RT) has an important role in the management of locally advanced rectal cancer (RC). Tumour regression following RT shows marked variability and robust molecular methods are needed with which to predict likely response. The aim of this study was to review the current published literature and employ Gene Ontology (GO) analysis to define key molecular biomarkers governing radiation response in RC.
Methods
A systematic review of electronic bibliographic databases (MEDLINE, Embase) was performed for original articles published between 2000 and 2015. Biomarkers were then classified according to biological function and incorporated into a hierarchical GO tree. Both significant and non-significant results were included in the analysis. Significance was binarized based on uni- and multivariate statistics. Significance scores were calculated for each biological domain (or node), and a direct acyclic graph was generated for intuitive mapping of biological pathways and markers involved in rectal cancer radiation response.
Results
72 individual biomarkers, across 74 studies, were identified through review. On highest order classification, molecular biomarkers falling within the domains of response to stress, cellular metabolism and pathways inhibiting apoptosis were found to be the most influential in predicting radiosensitivity.
Conclusions
Homogenising biomarker data from original articles using controlled GO terminology demonstrates that cellular mechanisms of response to radiotherapy in RC - in particular the metabolic response to radiotherapy - may hold promise in developing radiotherapeutic biomarkers with which to predict, and in the future modulate, radiation response.
Pre-operative radiotherapy (RT) has an important role in the management of locally advanced rectal cancer (RC). Tumour regression following RT shows marked variability and robust molecular methods are needed with which to predict likely response. The aim of this study was to review the current published literature and employ Gene Ontology (GO) analysis to define key molecular biomarkers governing radiation response in RC.
Methods
A systematic review of electronic bibliographic databases (MEDLINE, Embase) was performed for original articles published between 2000 and 2015. Biomarkers were then classified according to biological function and incorporated into a hierarchical GO tree. Both significant and non-significant results were included in the analysis. Significance was binarized based on uni- and multivariate statistics. Significance scores were calculated for each biological domain (or node), and a direct acyclic graph was generated for intuitive mapping of biological pathways and markers involved in rectal cancer radiation response.
Results
72 individual biomarkers, across 74 studies, were identified through review. On highest order classification, molecular biomarkers falling within the domains of response to stress, cellular metabolism and pathways inhibiting apoptosis were found to be the most influential in predicting radiosensitivity.
Conclusions
Homogenising biomarker data from original articles using controlled GO terminology demonstrates that cellular mechanisms of response to radiotherapy in RC - in particular the metabolic response to radiotherapy - may hold promise in developing radiotherapeutic biomarkers with which to predict, and in the future modulate, radiation response.
Date Issued
2019-06-01
Date Acceptance
2019-01-23
Citation
Clinical Colorectal Cancer, 2019, 18 (2), pp.e210-e222
ISSN
1533-0028
Publisher
Elsevier
Start Page
e210
End Page
e222
Journal / Book Title
Clinical Colorectal Cancer
Volume
18
Issue
2
Copyright Statement
© 2019 The Authors. Published by Elsevier Inc. Accepted manuscript available open access under a CC-BY-NC-ND Attribution 4.0 Licence 9https://creativecommons.org/licenses/by-nc-nd/4.0/)
Sponsor
Bowel Disease Research Foundation
Imperial College Healthcare NHS Trust- BRC Funding
National Institute of Health Research
Commission of the European Communities
Imperial College Healthcare NHS Trust- BRC Funding
Imperial College Healthcare NHS Trust- BRC Funding
Commission of the European Communities
Cancer Research UK
Micromass UK Ltd
Grant Number
RDA27
305940
RDB04 79560
RD207
617896
25038
WSSB_P72092
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Neoadjuvant therapy
Radiation tolerance
Radiotherapy
Rectal neoplasms
INDEPENDENT NEGATIVE PROGNOSTICATOR
NEOADJUVANT CHEMORADIOTHERAPY
TUMOR-REGRESSION
PREOPERATIVE CHEMORADIOTHERAPY
THYMIDYLATE-SYNTHASE
PREDICTIVE MARKER
DIHYDROPYRIMIDINE-DEHYDROGENASE
CONCURRENT CHEMORADIOTHERAPY
CYCLOOXYGENASE-2 EXPRESSION
HISTOPATHOLOGICAL RESPONSE
Neoadjuvant therapy
Radiation tolerance
Radiotherapy
Rectal neoplasms
1112 Oncology and Carcinogenesis
Oncology & Carcinogenesis
Publication Status
Published
Date Publish Online
2019-02-10